Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Adam Judge"'
Autor:
Anne Dallas, Heini Ilves, Joshua Shorenstein, Adam Judge, Ryan Spitler, Christopher Contag, Suet Ping Wong, Richard P Harbottle, Ian MacLachlan, Brian H Johnston
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 2, Iss C (2013)
We previously identified short synthetic shRNAs (sshRNAs) that target a conserved hepatitis C virus (HCV) sequence within the internal ribosome entry site (IRES) of HCV and potently inhibit HCV IRES-linked gene expression. To assess in vivo liver del
Externí odkaz:
https://doaj.org/article/cc3ef4ed86644013a09e86d0ed1bed5e
Autor:
Mark Wood, Lorne R. Palmer, Emily P. Thi, David Fraser, Sara A. Majeski, James Heyes, Agnes Jarosz, Kieu Lam, Adam Judge, Amy C.H. Lee, Alan D. Martin, Xin Ye, Kevin McClintock, Holland Richard J
Publikováno v:
Molecular Therapy. 29:2910-2919
N-Acetylgalactosamine (GalNAc) conjugated short interfering RNAs (siRNAs) are a leading RNA interference (RNAi) platform allowing targeted inhibition of disease-causing genes in hepatocytes. More than a decade of development has recently resulted in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fb0ff6e930ca9e409ab6c2a07d44a2d
https://doi.org/10.1016/j.ymthe.2021.06.002
https://doi.org/10.1016/j.ymthe.2021.06.002
Autor:
Adam Judge, Raul Ursic-Bedoya, Thomas W. Geisbert, Chad E. Mire, Joan B. Geisbert, Ian MacLachlan, Marjorie Robbins
Publikováno v:
The Journal of Infectious Diseases
Background. Marburg virus (MARV) infection causes severe morbidity and mortality in humans and nonhuman primates. Currently, there are no licensed therapeutics available for treating MARV infection. Here, we present the in vitro development and in vi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::987bfdc1349481bd1cff09d4d767f068
https://doi.org/10.1093/infdis/jit465
https://doi.org/10.1093/infdis/jit465
Autor:
Snorri S. Thorgeirsson, Daekwan Seo, Elizabeth A. Conner, Valentina M. Factor, Ho Taek Song, Yun-Han Lee, Ian MacLachlan, Tsuyoshi Ishikawa, Jesper B. Andersen, Hyun Goo Woo, Mitsuteru Kitade, Itzhak Avital, Marian E. Durkin, Adam Judge, Jens U. Marquardt, Chiara Raggi
Publikováno v:
Cancer Research. 70:8264-8269
The development of targeted therapeutics for hepatocellular carcinoma (HCC) remains a major challenge. The ubiquitination modulator COP1 regulates p53 activity by ubiquitination and it is frequently overexpressed in human HCC. In this study, we teste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219ff5452c5b093e0d994d738a451818
https://doi.org/10.1158/0008-5472.can-10-0749
https://doi.org/10.1158/0008-5472.can-10-0749
Autor:
Adam Judge, Ian MacLachlan
Publikováno v:
Human Gene Therapy. 19:111-124
Many types of nucleic acid, including canonical small interfering RNA (siRNA) duplexes, are potent activators of the mammalian innate immune system. Synthetic siRNA duplexes can induce high levels of inflammatory cytokines and type I interferons, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa1a8eb3e7a7a49f3acbf1040a71352
https://doi.org/10.1089/hum.2007.179
https://doi.org/10.1089/hum.2007.179
Publikováno v:
Molecular Therapy. 15(9):1663-1669
RNA molecules such as single-stranded RNA (ssRNA) and small interfering RNA (siRNA) duplexes induce Toll-like receptor (TLR)-mediated immune stimulation after intracellular delivery. We have previously shown that selective incorporation of 2'-O-methy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::017eda15893c8c9ee0bdc460b17e9891
Autor:
Ian MacLachlan, Erik Z. Yu, Joan B. Geisbert, Adam Judge, Amy C.H. Lee, Lloyd Jeffs, Kathleen M. Daddario-DiCaprio, Janet R. Phelps, Elliott Kagan, Lisa E. Hensley, Kevin McClintock, Thomas W. Geisbert, Peter B. Jahrling, Elizabeth A. Fritz
Publikováno v:
The Journal of Infectious Diseases
Background. Ebola virus (EBOV) infection causes a frequently fatal hemorrhagic fever (HF) that is refractory to treatment with currently available antiviral therapeutics. RNA interference represents a powerful, naturally occurring biological strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783f8229abf19a2e237a1d169d34fcc5
https://doi.org/10.1086/504267
https://doi.org/10.1086/504267
Autor:
Ivanka Toudjarska, Jürgen Soutschek, Vandana Sood, Kevin McClintock, Akin Akinc, Birgit Bramlage, Matthew N. Fedoruk, Timothy Racie, Adam Judge, Ian MacLachlan, Hans-Peter Vornlocher, Lorne R. Palmer, Lloyd Jeffs, Kieu Lam, Sumi Shanmugam, William Zedalis, Tracy Zimmermann, Ingo Röhl, Matthias John, Ed Yaworski, Jens Harborth, Amy C.H. Lee, Muthiah Manoharan, Stephan Seiffert, James Heyes, David Bumcrot, Amanda J. Wheat, Victor Koteliansky, Lubomir Nechev
Publikováno v:
Nature. 441:111-114
The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bf5bcd46f67e5d2c5a34ff185d98a71
https://doi.org/10.1038/nature04688
https://doi.org/10.1038/nature04688
Publikováno v:
Molecular Therapy. 13:328-337
The systemic application of nucleic acid drugs requires delivery systems that overcome the poor pharmacokinetics, limited biodistribution, and inefficient uptake of nucleic acids. PEGylated liposomes show considerable promise because of their intrins
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd1726aa259741508897d1391d234728
https://doi.org/10.1016/j.ymthe.2005.09.014
https://doi.org/10.1016/j.ymthe.2005.09.014
Autor:
Daekwan Seo, Mitsuteru Kitade, Chiara Raggi, Luis Enrique Gómez-Quiroz, Snorri S. Thorgeirsson, Ian MacLachlan, Elizabeth A. Conner, Jens U. Marquardt, Jesper B. Andersen, Valentina M. Factor, Min Ah Won, Yun-Han Lee, Adam Judge, Kyung Ju Choi
Publikováno v:
Cancer research. 74(17)
Histone deacetylase 2 (HDAC2) is a chromatin modifier involved in epigenetic regulation of cell cycle, apoptosis, and differentiation that is upregulated commonly in human hepatocellular carcinoma (HCC). In this study, we show that specific targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7eef0e1b2925379e9cf5c3c0ab0f0e
https://pubmed.ncbi.nlm.nih.gov/24958469
https://pubmed.ncbi.nlm.nih.gov/24958469